Claims for Patent: 8,754,078

Summary for Patent: 8,754,078

Title:	Compositions and methods for treatment of cancer
Abstract:	The present invention relates to pyrroloquinolinyl-pyrrolidine-2,5-dione compounds in combination with chemotherapeutic agents. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or pyrroloquinolinyl-pyrrolidine-2,5-dione compound of the present invention and also administering a effective amount of a chemotherapeutic agent.
Inventor(s):	Li; Chiang J. (West Roxbury, MA), Ashwell; Mark A. (Carlisle, MA), Hill; Jason (Auburndale, MA), Moussa; Magdi M. (Malden, MA), Munshi; Neru (Burlington, MA)
Assignee:	ArQule, Inc. (Woburn, MA)
Application Number:	13/761,712
Patent Claims:	1. A pharmaceutical composition comprising a first chemotherapeutic agent including a pyrroloquinolinyl-pyrrolidine-2,5-dione compound of formula IVa, IVb, Va, or Vb, or pharmaceutically acceptable salts thereof: ##STR00036## where: R1, R2 and R3 are independently selected from the group consisting of hydrogen, F, Cl, Br, I, --NR5R6, --(C.sub.1-C.sub.6) alkyl, --(C.sub.1-C.sub.6) substituted alkyl, --(C.sub.3-C.sub.9) cycloalkyl, --(C.sub.3-C.sub.9) substituted cycloalkyl, --O--(C.sub.1-C.sub.6) alkyl, --O--(C.sub.1-C.sub.6) substituted alkyl, --O--(C.sub.3-C.sub.9) cycloalkyl, and --O--(C.sub.3-C.sub.9) substituted cycloalkyl, aryl, heteroaryl, heterocyclyl; R4 is independently selected from the group consisting of hydrogen, --(C.sub.1-C.sub.6) alkyl, and --CH.sub.2R7; R5, R6 are independently selected from the group consisting of hydrogen, and --(C.sub.1-C.sub.6) alkyl; R7 is independently selected from the group consisting of --O--P(.dbd.O)(OH).sub.2, --O--P(.dbd.O)(--OH)(--O--(C.sub.1-C.sub.6) alkyl), --O--P(.dbd.O)(--O--(C.sub.1-C.sub.6) alkyl).sub.2, --O--P(.dbd.O)(--OH) (--O--(CH.sub.2)-phenyl), --O--P(.dbd.O)(--O--(CH.sub.2)-phenyl).sub.2, a carboxylic acid group, an amino carboxylic acid group and a peptide; Q is selected from the group consisting of aryl, heteroaryl, --O-aryl, --S-aryl, --O-heteroaryl, and --S-heteroaryl; wherein said aryl, heteroaryl, --O-aryl, --S-aryl, --O-heteroaryl, and --S-heteroaryl groups may be substituted with one or more substituents independently selected from the group consisting of F, Cl, Br, I, --NR5R6, --(C.sub.1-C.sub.6) alkyl, --(C.sub.1-C.sub.6) substituted alkyl, --(C.sub.3-C.sub.9) cycloalkyl, --(C.sub.3-C.sub.9) substituted cycloalkyl, --O--(C.sub.1-C.sub.6) alkyl, --O--(C.sub.1-C.sub.6) substituted alkyl, --O--(C.sub.3-C.sub.9) cycloalkyl, --O--(C.sub.3-C.sub.9) substituted cycloalkyl, -aryl, -aryl-(C.sub.1-C.sub.6) alkyl, -aryl-O--(C.sub.1-C.sub.6) alkyl, --O-aryl, --O--(C.sub.1-C.sub.4) alkyl-aryl, heteroaryl, heterocyclyl, --O--(C.sub.1-C.sub.4) alkyl-heterocyclyl, and --(S(.dbd.O).sub.2)--(C.sub.1-C.sub.6) alkyl; and further comprising an effective amount of a second chemotherapeutic agent selected from the group consisting of tamoxifen, raloxifene, anastrozole, exemestane, letrozole, trastuzumab, imatinib, paclitaxel, cyclophosphamide, lovastatin, mimosine, gemcitabine, araC, 5-fluorouracil, methotrexate, docetaxel, goserelin, vincristine, vinblastine, nocodazole, teniposide, etoposide, epothilone, navelbine, camptothecin, daunorubicin, dactinomycin, mitoxantrone, amsacrine, doxorubicin, epirubicin and idarubicin. 2. A method of treating a cell proliferative disorder, said method comprising administering to a subject in need thereof a therapeutically effective amount of a first chemotherapeutic agent including a pyrroloquinolinyl-pyrrolidine-2,5-dione compound of formula IVa, IVb, Va, or Vb, or pharmaceutically acceptable salts thereof: ##STR00037## where: R1, R2 and R3 are independently selected from the group consisting of hydrogen, F, Cl, Br, I, --NR5R6, --(C.sub.1-C.sub.6) alkyl, --(C.sub.1-C.sub.6) substituted alkyl, --(C.sub.3-C.sub.9) cycloalkyl --(C.sub.3-C.sub.9) substituted cycloalkyl, --O--(C.sub.1-C.sub.6) alkyl, --O--(C.sub.1-C.sub.6) substituted alkyl, --O--(C.sub.3-C.sub.9) cycloalkyl, and --O--(C.sub.3-C.sub.9) substituted cycloalkyl, aryl, heteroaryl, heterocyclyl; R4 is independently selected from the group consisting of hydrogen --(C.sub.1-C.sub.6) alkyl, and --CH.sub.2R7; R5, R6 are independently selected from the group consisting of hydrogen, and --(C.sub.1-C.sub.6) alkyl; R7 is independently selected from the group consisting of --O--P(.dbd.O)(OH).sub.2, --O--P(.dbd.O)(--OH)(--O--(C.sub.1-C.sub.6) alkyl), --O--P(.dbd.O)(--O--(C.sub.1-C.sub.6) alkyl).sub.2, --O--P(.dbd.O)(--OH)(--O--(CH.sub.2)-phenyl), --O--P(.dbd.O)(--O--(CH.sub.2)-phenyl).sub.2, a carboxylic acid group, an amino carboxylic acid group and a peptide; Q is selected from the group consisting of aryl, heteroaryl, --O-aryl, --S-aryl, --O-heteroaryl, and --S-heteroaryl; wherein said aryl, heteroaryl, --O-aryl, --S-aryl, --O-heteroaryl, and --S-heteroaryl groups may be substituted with one or more substituents independently selected from the group consisting of F, Cl, Br, I, --NR5R6, --(C.sub.1-C.sub.6) alkyl, --(C.sub.1-C.sub.6) substituted alkyl, --(C.sub.3-C.sub.9) cycloalkyl, --(C.sub.3-C.sub.9) substituted cycloalkyl, --O--(C.sub.1-C.sub.6) alkyl, --O--(C.sub.1-C.sub.6) substituted alkyl, --O--(C.sub.3-C.sub.9) cycloalkyl, --O--(C.sub.3-C.sub.9) substituted cycloalkyl, -aryl, -aryl-(C.sub.1-C.sub.6) alkyl, -aryl-O--(C.sub.1-C.sub.6) alkyl, --O-aryl, --O--(C.sub.1-C.sub.4) alkyl-aryl, heteroaryl, heterocyclyl, --O--(C.sub.1-C.sub.4) alkyl-heterocyclyl, and --(S(.dbd.O).sub.2)--(C.sub.1-C.sub.6) alkyl; and administering an effective amount of a second chemotherapeutic agent selected from the group consisting of tamoxifen, raloxifene, anastrozole, exemestane, letrozole, trastuzumab, imatinib, paclitaxel, cyclophosphamide, lovastatin, mimosine, gemcitabine, araC, 5-fluorouracil, methotrexate, docetaxel, goserelin, vincristine, vinblastine, nocodazole, teniposide, etoposide, epothilone, navelbine, camptothecin, daunorubicin, dactinomycin, mitoxantrone, amsacrine, doxorubicin, epirubicin and idarubicin, wherein said cell proliferative disorder is one of small cell lung cancer, lung cancer, colon cancer, breast cancer, pancreatic cancer, prostate cancer, chronic myelogenous leukemia, melanoma, or ovarian cancer. 3. The method of claim 2 wherein said treating said cell proliferative disorder comprises a reduction in tumor size. 4. The method of claim 2, wherein said cell proliferative disorder is a disorder of metastatic proliferative cells. 5. The method of claim 2, wherein said treating said cell proliferative disorder comprises inhibition of metastatic cancer cell invasion. 6. The method of claim 2, wherein the pyrroloquinolinyl-pyrrolidine-2,5-dione compound is selected from the group consisting of (+)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4(1H-indol-3-yl)- pyrrolidine-2,5-dione, (-)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4(1H-indol-3-yl)- pyrrolidine-2,5-dione, (+)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4(1H-indol-3-- yl)pyrrolidine-2,5-dione, and (-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4(1H-indol-3-- yl)pyrrolidine-2,5-dione. 7. The method of claim 2, wherein the pyrroloquinolinyl-pyrrolidine-2,5-dione compound is (-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4(1H-indol-3-- yl)pyrrolidine-2,5-dione. 8. The method of claim 2, wherein the cells with proliferative disorder contains DNA encoding c-Met. 9. The method of claim 8, wherein the cells have a constitutively enhanced c-Met activity. 10. The composition of claim 1 together with one or more pharmaceutically acceptable carriers or excipients. 11. The method of claim 2 wherein the compound and the chemotherapeutic agent are administered with one or more pharmaceutically acceptable carriers or excipients. 12. The method of claim 2, wherein the administering the compound and administering the chemotherapeutic agent are performed as a single procedure. 13. The compound of claim 1 is selected from the group consisting of (+)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2,5-dione, (-)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4(1H-indol-3-yl)- pyrrolidine-2,5-dione, (+)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4(1H-indol-3-- yl)pyrrolidine-2,5-dione, and (-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4(1H-indol-3-- yl)pyrrolidine-2,5-dione. 14. The compound of claim 1, where Q is an indolyl group or an indolyl group substituted with one or more substituents independently selected from the group consisting of: F, Cl, Br, I, --(C.sub.1-C.sub.6) alkyl, --(C.sub.1-C.sub.6)fluoro-substituted alkyl, --(C.sub.3-C.sub.9) cycloalkyl, --(C.sub.3-C.sub.9) fluoro-substituted cycloalkyl, --O--(C.sub.1-C.sub.6) alkyl, --O--(C.sub.1-C.sub.6) fluoro-substituted alkyl, --O--(C.sub.3-C.sub.9) cycloalkyl, and --O--(C.sub.3-C.sub.9) fluoro-substituted cycloalkyl, -aryl, --O-aryl, --O-- (C.sub.1-C.sub.4) alkyl-aryl, --O-- (C.sub.1-C.sub.4) alkyl-heterocycle, and --S(.dbd.O).sub.2--(C.sub.1-C.sub.6) alkyl. 15. The compound of claim 1, wherein R4 is --CH.sub.2R7, and R7 is --O--P(.dbd.O)(OH).sub.2, --O--P(.dbd.O)(--OH)(--O--(C.sub.1-C.sub.6) alkyl), --O--P(.dbd.O)(--O--(C.sub.1-C.sub.6) alkyl).sub.2, a carboxylic acid group, an amino carboxylic acid group or a peptide. 16. The compound of claim 15, wherein R7 is --O--P(.dbd.O)(OH).sub.2, --O--P(.dbd.O)(--OH)(--O--(C.sub.1-C.sub.6) alkyl), or --O--P(.dbd.O)(--O--(C.sub.1-C.sub.6) alkyl).sub.2. 17. The compound of claim 15, wherein R7 is a carboxylic acid group, an amino carboxylic acid group or a peptide. 18. The compound of claim 15, where R7 is alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine. 19. The compound of claim 18, where R7 is L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-cysteine, L-glutamine, L-glutamic acid, L-glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-proline, L- serine, L-threonine, L-tryptophan, L-tyrosine, or L-valine. 20. The compound of claim 17, where R7 is a peptide. 21. The compound of claim 20, wherein said peptide is comprised of two or more imino or amino acids selected from the group consisting of: L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-cysteine, L-glutamine, L-glutamic acid, L-glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, and L-valine. 22. The method of claim 2, where Q is an indolyl group or an indolyl group substituted with one or more substituents independently selected from the group consisting of: F, Cl, Br, I, --(C.sub.1-C.sub.6) alkyl, --(C.sub.1-C.sub.6)fluoro-substituted alkyl, --(C.sub.3-C.sub.9) cycloalkyl, --(C.sub.3-C.sub.9) fluoro-substituted cycloalkyl, --O--(C.sub.1-C.sub.6) alkyl, --O--(C.sub.1-C.sub.6) fluoro-substituted alkyl, --O--(C.sub.3-C.sub.9) cycloalkyl, and --O--(C.sub.3-C.sub.9) fluoro-substituted cycloalkyl, -aryl, --O-aryl, --O-- (C.sub.1-C.sub.4) alkyl-aryl, --O--(C.sub.1-C.sub.4) alkyl-heterocycle, and --S(.dbd.O).sub.2--(C.sub.1-C.sub.6) alkyl. 23. The method of claim 2, wherein R4 is --CH.sub.2R7, and R7 is --O--P(.dbd.O)(OH).sub.2, --O--P(.dbd.O)(--OH)(--O--(C.sub.1-C.sub.6) alkyl), --O--P(.dbd.O)(--O--(C.sub.1-C.sub.6) alkyl).sub.2, a carboxylic acid group, an amino carboxylic acid group or a peptide. 24. The compound of claim 23, wherein R7 is --O--P(.dbd.O)(OH).sub.2, --O--P(.dbd.O)(--OH)(--O--(C.sub.1-C.sub.6) alkyl), or --O--P(.dbd.O)(--O--(C.sub.1-C.sub.6) alkyl).sub.2. 25. The method of claim 23, wherein R7 is a carboxylic acid group, an amino carboxylic acid group or a peptide. 26. The method of claim 25, where R7 is alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine. 27. The method of claim 26, where R7 is L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-cysteine, L-glutamine, L-glutamic acid, L-glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, or L-valine. 28. The method of claim 23, where R7 is a peptide. 29. The method of claim 28, wherein said peptide is comprised of two or more imino or amino acids selected from the group consisting of: L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-cysteine, L-glutamine, L-glutamic acid, L-glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, and L-valine.

Details for Patent 8,754,078

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2025-02-09
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2025-02-09
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2025-02-09